Lilly challenges Canada’s decision to strike down patents for not meeting “inventive promise”BMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f5651 (Published 17 September 2013) Cite this as: BMJ 2013;347:f5651
- Owen Dyer
The US drug giant Eli Lilly has filed suit against Canada, claiming that the country’s courts have arbitrarily struck down its patents. The company is seeking $500m (£315m; €375m) in alleged lost business under the terms of the North American Free Trade Agreement (NAFTA).
Two Canadian patents—those for atomoxetine (marketed as Strattera), used to treat attention-deficit/hyperactivity disorder (ADHD), and the antipsychotic olanzapine (Zyprexa)—were voided early by …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial